Navigation

2006/013 NICE issues guidance on drug treatments for attention deficit hyperactivity disorder (ADHD)

The National Institute for Health and Care Excellence (NICE) today (22 March) issued guidance to the NHS in England and Wales on the use of methylphenidate, atomoxetine and dexamfetamine for treating attention deficit hyperactivity disorder (ADHD) in children and adolescents. This updates previous guidance (TA no. 13) issued in October 2000, which gave recommendations on methylphenidate only.

This page was last updated: 03 August 2007

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.